Role of yavalauha churna in dyslipidemia
Phase 2
- Conditions
- Health Condition 1: - Health Condition 2: - Health Condition 3: - Health Condition 4: E789- Disorder of lipoprotein metabolism, unspecified
- Registration Number
- CTRI/2019/09/021369
- Lead Sponsor
- SGT University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Patients willing for trial is the foremost criteria.
2. Patients having one or more parameters of deranged lipid profile.
Exclusion Criteria
1. Patients having serious ailments like Type 1 DM or poorly controlled Type 2 DM, MI, Cardiac failure, Renal insufficiency, Hypothyroidism, Glucocortico-steroids induced dyslipidemia.
2. Patients on statins/any other drug.
3. The patients more than 40 BMI will not be taken.
4. Pregnant females and lactating mothers.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1.Symptomatically, patients will be evaluated as per the scoring pattern. <br/ ><br>2.Changes in objective criteria i.e. lipid profile will be analysed and effectiveness of trial drug will be evaluated. <br/ ><br>3.normalcy of lipid profile will be the main primary outcome.Timepoint: 1.Symptomatically, patients will be evaluated as per the scoring pattern. <br/ ><br>2.Changes in objective criteria i.e. lipid profile will be done on baseline, after 2 months and then one month after completion of the therapy.
- Secondary Outcome Measures
Name Time Method It is expected that weight and hence, BMI of the patients will be reduced during and after the treatment.Timepoint: BMI will be reduced.